Leerink Partnrs Has Negative Estimate for JNJ Q3 Earnings

Johnson & Johnson (NYSE:JNJ) – Analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for Johnson & Johnson in a research report issued to clients and investors on Thursday, July 17th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $2.65 per share for the quarter, down from their previous forecast of $2.74. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.58 per share. Leerink Partnrs also issued estimates for Johnson & Johnson’s Q4 2025 earnings at $2.68 EPS, FY2025 earnings at $10.87 EPS, FY2026 earnings at $11.42 EPS, FY2027 earnings at $12.30 EPS and FY2029 earnings at $14.88 EPS.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. Johnson & Johnson’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.82 EPS.

JNJ has been the subject of a number of other research reports. Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Guggenheim upped their target price on Johnson & Johnson from $164.00 to $167.00 and gave the stock a “neutral” rating in a research note on Thursday. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday. Finally, UBS Group reiterated a “buy” rating and issued a $190.00 target price (up previously from $180.00) on shares of Johnson & Johnson in a research report on Thursday. Eleven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $172.87.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $163.65 on Friday. The business’s 50 day moving average is $154.29 and its 200-day moving average is $154.97. The firm has a market cap of $393.75 billion, a P/E ratio of 17.50, a price-to-earnings-growth ratio of 2.18 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds have recently modified their holdings of the business. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the 4th quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.